{"id":2589547,"date":"2023-11-24T19:00:00","date_gmt":"2023-11-25T00:00:00","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/the-therapeutic-effects-and-potential-mechanisms-of-endoscopic-submucosal-injection-of-mesenchymal-stem-cells-on-chronic-atrophic-gastritis-a-study-in-scientific-reports\/"},"modified":"2023-11-24T19:00:00","modified_gmt":"2023-11-25T00:00:00","slug":"the-therapeutic-effects-and-potential-mechanisms-of-endoscopic-submucosal-injection-of-mesenchymal-stem-cells-on-chronic-atrophic-gastritis-a-study-in-scientific-reports","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/the-therapeutic-effects-and-potential-mechanisms-of-endoscopic-submucosal-injection-of-mesenchymal-stem-cells-on-chronic-atrophic-gastritis-a-study-in-scientific-reports\/","title":{"rendered":"The Therapeutic Effects and Potential Mechanisms of Endoscopic Submucosal Injection of Mesenchymal Stem Cells on Chronic Atrophic Gastritis: A Study in Scientific Reports"},"content":{"rendered":"

\"\"<\/p>\n

Title: The Therapeutic Potential of Endoscopic Submucosal Injection of Mesenchymal Stem Cells for Chronic Atrophic Gastritis<\/p>\n

Introduction:
\nChronic atrophic gastritis (CAG) is a common gastrointestinal disorder characterized by the progressive inflammation and degeneration of the gastric mucosa. It is often associated with Helicobacter pylori infection, autoimmune diseases, or long-term use of certain medications. CAG can lead to various complications, including gastric ulcers, intestinal metaplasia, and an increased risk of gastric cancer. Current treatment options for CAG are limited, and there is a need for innovative therapeutic approaches. In recent years, the use of mesenchymal stem cells (MSCs) has emerged as a promising strategy for the treatment of various diseases, including CAG. This article aims to explore the therapeutic effects and potential mechanisms of endoscopic submucosal injection of MSCs on chronic atrophic gastritis.<\/p>\n

Therapeutic Effects of MSCs on Chronic Atrophic Gastritis:
\n1. Anti-inflammatory properties: MSCs possess potent immunomodulatory properties, which can help reduce the chronic inflammation associated with CAG. They can suppress the activation and proliferation of immune cells, such as T cells and macrophages, thereby reducing the release of pro-inflammatory cytokines.<\/p>\n

2. Tissue regeneration: MSCs have the ability to differentiate into various cell types, including gastric epithelial cells. When injected into the gastric submucosa, MSCs can promote tissue repair and regeneration by differentiating into functional gastric cells and stimulating the proliferation of endogenous stem cells.<\/p>\n

3. Paracrine effects: MSCs secrete a wide range of bioactive molecules, such as growth factors, cytokines, and extracellular vesicles. These paracrine factors can modulate the local microenvironment, promote angiogenesis, inhibit apoptosis, and enhance tissue healing processes.<\/p>\n

Potential Mechanisms of MSC Therapy for Chronic Atrophic Gastritis:
\n1. Immunomodulation: MSCs can modulate the immune response by suppressing the activity of immune cells and promoting the generation of regulatory T cells. This immunomodulatory effect helps to reduce the chronic inflammation in the gastric mucosa and promote tissue repair.<\/p>\n

2. Trophic effects: MSCs secrete various growth factors, such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). These factors promote angiogenesis, stimulate cell proliferation, and enhance tissue regeneration in the damaged gastric mucosa.<\/p>\n

3. Extracellular vesicles: MSC-derived extracellular vesicles, including exosomes, contain a variety of bioactive molecules, such as microRNAs and proteins. These vesicles can be taken up by recipient cells and exert therapeutic effects by modulating gene expression, promoting cell survival, and reducing inflammation.<\/p>\n

Clinical Studies:
\nSeveral preclinical and clinical studies have investigated the therapeutic potential of endoscopic submucosal injection of MSCs for chronic atrophic gastritis. These studies have shown promising results, including improved gastric mucosal thickness, reduced inflammation, and enhanced tissue regeneration. However, further research is needed to optimize the delivery methods, dosage, and long-term safety of MSC therapy for CAG.<\/p>\n

Conclusion:
\nEndoscopic submucosal injection of mesenchymal stem cells holds great promise as a novel therapeutic approach for chronic atrophic gastritis. The immunomodulatory properties, tissue regenerative capacity, and paracrine effects of MSCs contribute to their therapeutic effects. Understanding the underlying mechanisms of MSC therapy will pave the way for the development of more effective and targeted treatments for CAG. Further research and clinical trials are necessary to establish the safety and efficacy of this innovative approach in the management of chronic atrophic gastritis.<\/p>\n